This inhibitory mechanism is continuously exploited in both mouse and human cell line prostate cancer models where mTORC2 signaling is constitutively activated by PTEN deficiency or loss, contributing to prostate cancer progression (Figure 2 bottom panel) [52]. Here, PTEN is linked to prostate carcinoma.